Taysha Gene Therapies
TSHA
155 hedge funds and large institutions have $866M invested in Taysha Gene Therapies in 2025 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 61 increasing their positions, 34 reducing their positions, and 20 closing their positions.
104% more call options, than puts
Call options by funds: $1.66M | Put options by funds: $813K
79% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 34
45% more capital invested
Capital invested by funds: $595M → $866M (+$270M)
40% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 20
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
3% more funds holding
Funds holding: 150 → 155 (+5)
23.05% less ownership
Funds ownership: 120.06% → 97% (-23%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$13.3M |
| 2 |
BlackRock
New York
|
+$8.67M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$7.93M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$7.08M |
| 5 |
Morgan Stanley
New York
|
+$6.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
-$23.1M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$9.98M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$7.94M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$7.43M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$6.82M |
TSHA Hedge Fund Activity: Q3 2025 in Review
155 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q3 2025, worth a combined $866M — up 45% from $595M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new TSHA positions and 20 closed out — a net gain of 8 holders — while 61 added to existing stakes and 34 trimmed.
The largest buyer was Barclays, adding an estimated $13.3M. The largest seller was Jefferies Financial Group, cutting an estimated $23.1M.
- 155 institutional investors held Taysha Gene Therapies (TSHA) as of Q3 2025, up from 150 in Q2 2025.
- Funds reported $866M of Taysha Gene Therapies stock for Q3 2025, up 45% quarter-over-quarter.
- 28 funds opened new Taysha Gene Therapies positions in Q3 2025 and 20 closed out, a net change of +8 holders.
- The largest Taysha Gene Therapies buyer in Q3 2025 was Barclays, an estimated $13.3M added.
- The largest Taysha Gene Therapies seller in Q3 2025 was Jefferies Financial Group, an estimated $23.1M sold.
Based on aggregated 13F filings for Q3 2025.